THE SEER PROGRAM CODE MANUAL

CANCER STATISTICS BRANCH
SURVEILLANCE PROGRAM
DIVISION OF CANCER PREVENTION AND CONTROL
NATIONAL CANCER INSTITUTE

Effective Date: Cases Diagnosed January 1, 1988
Revised: May, 1988
Revised: January, 1989
Revised: January, 1990
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>COMPUTER RECORD FORMAT</td>
<td>1</td>
</tr>
<tr>
<td>INTRODUCTION AND GENERAL INSTRUCTIONS</td>
<td>6</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>37</td>
</tr>
<tr>
<td>SEER CODE SUMMARY</td>
<td>38</td>
</tr>
<tr>
<td>I BASIC RECORD IDENTIFICATION</td>
<td>52</td>
</tr>
<tr>
<td>I.01 SEER Participant</td>
<td>53</td>
</tr>
<tr>
<td>I.02 Case Number</td>
<td>54</td>
</tr>
<tr>
<td>I.03 Record Number</td>
<td>55</td>
</tr>
<tr>
<td>II INFORMATION SOURCE</td>
<td>56</td>
</tr>
<tr>
<td>II.01 Type of Reporting Source</td>
<td>57</td>
</tr>
<tr>
<td>II.02 Field Not Used</td>
<td>58</td>
</tr>
<tr>
<td>III DEMOGRAPHIC INFORMATION</td>
<td>59</td>
</tr>
<tr>
<td>III.01 Place of Residence at Diagnosis</td>
<td>60</td>
</tr>
<tr>
<td>III.02 Field Not Used</td>
<td>64</td>
</tr>
<tr>
<td>III.03 Place of Birth</td>
<td>65</td>
</tr>
<tr>
<td>III.04 Date of Birth</td>
<td>66</td>
</tr>
<tr>
<td>III.05 Age at Diagnosis</td>
<td>67</td>
</tr>
<tr>
<td>III.06 Race</td>
<td>68</td>
</tr>
<tr>
<td>III.07 Spanish Surname or Origin</td>
<td>69</td>
</tr>
<tr>
<td>III.08 Sex</td>
<td>70</td>
</tr>
<tr>
<td>III.09 Marital Status at Diagnosis</td>
<td>71</td>
</tr>
<tr>
<td>III.10 Field Not Used</td>
<td>72</td>
</tr>
<tr>
<td>IV DESCRIPTION OF THIS NEOPLASM</td>
<td>73</td>
</tr>
<tr>
<td>IV.01 Date of Diagnosis</td>
<td>74</td>
</tr>
<tr>
<td>IV.02 Sequence Number</td>
<td>76</td>
</tr>
<tr>
<td>IV.03 Primary Site</td>
<td>78</td>
</tr>
<tr>
<td>IV.04 Field Not Used</td>
<td>80</td>
</tr>
<tr>
<td>IV.05 Laterality at Diagnosis</td>
<td>81</td>
</tr>
<tr>
<td>IV.06 Morphology</td>
<td>83</td>
</tr>
<tr>
<td>IV.07 Tumor Markers</td>
<td>89</td>
</tr>
<tr>
<td>IV.08 Diagnostic Confirmation</td>
<td>90</td>
</tr>
<tr>
<td>IV.09 Field Not Used</td>
<td>92</td>
</tr>
<tr>
<td>IV.10 Diagnostic Procedures (1973-87)</td>
<td>93</td>
</tr>
</tbody>
</table>

# TABLE OF CONTENTS

## IV DESCRIPTION OF THIS NEOPLASM (cont'd)
- IV.11 Field Not Used
- IV.12 Coding System for Extent of Disease
- IV.13 Extent of Disease (EOD)
  - A SEER Nonspecific (1973-82)
  - B SEER Two-digit (1973-82)
  - C SEER Expanded (13-digit) Site-specific (1973-82)
  - D SEER 4-digit Extent of Disease (1983-87)
- IV.14 Field Not Used

## V FIRST COURSE OF CANCER-DIRECTED THERAPY
- V.01 Date Therapy Initiated
- V.02 Surgery
  - A Site-specific Surgery
  - B Reason for No Cancer-Directed Surgery
- V.03 Radiation
- V.04 Radiation to the Brain and Central Nervous System
- V.05 Radiation Sequence with Surgery
- V.06 Chemotherapy
- V.07 Endocrine (Hormone/Steroid) Therapy
- V.08 Biological Response Modifiers
- V.09 Other Cancer-directed Therapy
- V.10 Field Not Used

## VI FOLLOW-UP INFORMATION
- VI.01 Date of Last Follow-Up or of Death
- VI.02 Vital Status
- VI.03 ICD Code Used for Cause of Death
- VI.04 Underlying Cause of Death
- VI.05 Type of Follow-Up
- VI.06 Field Not Used

## VII ADMINISTRATIVE CODES
- VII.01 Site/Type Interfield Review
- VII.02 Histology/Behavior Interfield Review
- VII.03 Age/Site/Histology Interfield Review
- VII.04 Sequence Number/Diagnostic Confirmation Interfield Review
- VII.05 Site/Histology/Laterality/Sequence Number Interrecord Review
- VII.06 Surgery/Diagnostic Confirmation Interfield Review
- VII.07 Type of Reporting Source/Sequence Number Interfield Review
- VII.08 Sequence Number/ill-defined Site Interfield Review
**TABLE OF CONTENTS**

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV DESCRIPTION OF THIS NEOPLASM (cont’d)</td>
<td></td>
</tr>
<tr>
<td>VII.09 Leukemia or Lymphoma/Diagnostic Confirmation Interfield Review</td>
<td>131</td>
</tr>
<tr>
<td>VII.10 Field Not Used</td>
<td>132</td>
</tr>
<tr>
<td>APPENDIX A -- County Codes</td>
<td>133</td>
</tr>
<tr>
<td>APPENDIX B -- SEER Geocodes for Coding Place of Birth</td>
<td>139</td>
</tr>
<tr>
<td>APPENDIX C -- Site-specific Surgery Codes</td>
<td>157</td>
</tr>
<tr>
<td>APPENDIX D -- Coding Exceptions for Pre-1988 Cases</td>
<td>197</td>
</tr>
<tr>
<td>APPENDIX E -- Coding Changes for Post-1989 Cases</td>
<td>255</td>
</tr>
<tr>
<td>INDEX</td>
<td>257</td>
</tr>
</tbody>
</table>
The format of the data to be submitted to the National Cancer Institute by the participants of the SEER Program is as follows:

<table>
<thead>
<tr>
<th>Field</th>
<th>Section Number</th>
<th>Char. Length</th>
<th>Pos. Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>I BASIC RECORD IDENTIFICATION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I.01 SEER Participant</td>
<td>2</td>
<td>1-2</td>
<td>55</td>
</tr>
<tr>
<td>I.02 Case Number</td>
<td>8</td>
<td>3-10</td>
<td>55</td>
</tr>
<tr>
<td>I.03 Record Number</td>
<td>2</td>
<td>11-12</td>
<td>55</td>
</tr>
<tr>
<td>II INFORMATION SOURCE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II.01 Type of Reporting Source</td>
<td>1</td>
<td>13</td>
<td>57</td>
</tr>
<tr>
<td>II.02 Field Not Used</td>
<td>10</td>
<td>14-23</td>
<td>58</td>
</tr>
<tr>
<td>III DEMOGRAPHIC INFORMATION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III.01 Place of Residence at Diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A County</td>
<td>3</td>
<td>24-26</td>
<td>61</td>
</tr>
<tr>
<td>B Census Tract</td>
<td>3</td>
<td>27-32</td>
<td>62</td>
</tr>
<tr>
<td>C Coding System for Census Tract</td>
<td>1</td>
<td>33</td>
<td>63</td>
</tr>
<tr>
<td>III.02 Field Not Used</td>
<td>1</td>
<td>34</td>
<td>64</td>
</tr>
<tr>
<td>III.03 Place of Birth</td>
<td>3</td>
<td>35-37</td>
<td>65</td>
</tr>
<tr>
<td>III.04 Date of Birth</td>
<td>6</td>
<td>38-43</td>
<td>66</td>
</tr>
<tr>
<td>III.05 Age at Diagnosis</td>
<td>3</td>
<td>44-46</td>
<td>67</td>
</tr>
<tr>
<td>III.06 Race</td>
<td>2</td>
<td>47-48</td>
<td>68</td>
</tr>
<tr>
<td>III.07 Spanish Surname or Origin</td>
<td>1</td>
<td>49</td>
<td>69</td>
</tr>
<tr>
<td>III.08 Sex</td>
<td>1</td>
<td>50</td>
<td>70</td>
</tr>
<tr>
<td>III.09 Marital Status at Diagnosis</td>
<td>1</td>
<td>51</td>
<td>71</td>
</tr>
<tr>
<td>III.10 Field Not Used</td>
<td>20</td>
<td>52-71</td>
<td>72</td>
</tr>
<tr>
<td>IV DESCRIPTION OF THIS NEOPLASM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV.01 Date of Diagnosis</td>
<td>6</td>
<td>72-77</td>
<td>74</td>
</tr>
<tr>
<td>IV.02 Sequence Number</td>
<td>2</td>
<td>78-79</td>
<td>76</td>
</tr>
<tr>
<td>IV.03 Primary Site</td>
<td>3</td>
<td>80-82</td>
<td>78</td>
</tr>
<tr>
<td>IV.04 Field Not Used</td>
<td>1</td>
<td>83</td>
<td>80</td>
</tr>
<tr>
<td>IV.05 Laterality at Diagnosis</td>
<td>1</td>
<td>84</td>
<td>81</td>
</tr>
<tr>
<td>IV.06 Morphology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A Histologic Type</td>
<td>4</td>
<td>85-88</td>
<td>85</td>
</tr>
<tr>
<td>B Behavior</td>
<td>1</td>
<td>89</td>
<td>86</td>
</tr>
<tr>
<td>C Grade, Differentiation, or Cell Indicator</td>
<td>1</td>
<td>90</td>
<td>87</td>
</tr>
<tr>
<td>IV.07 Tumor Markers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A Tumor Marker 1</td>
<td>1</td>
<td>91</td>
<td>89.1</td>
</tr>
<tr>
<td>B Tumor Marker 2</td>
<td>1</td>
<td>92</td>
<td>89.2</td>
</tr>
<tr>
<td>IV.08 Diagnostic Confirmation</td>
<td>1</td>
<td>93</td>
<td>90</td>
</tr>
<tr>
<td>IV.09 Field Not Used</td>
<td>1</td>
<td>94</td>
<td>92</td>
</tr>
<tr>
<td>IV.10 Diagnostic Procedures (1973-87)</td>
<td>2</td>
<td>95-96</td>
<td>93</td>
</tr>
<tr>
<td>Field</td>
<td>Section Number</td>
<td>Char. Length</td>
<td>Pos. Page</td>
</tr>
<tr>
<td>-------</td>
<td>----------------</td>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>IV.11</td>
<td>Field Not Used</td>
<td>1 97</td>
<td>94</td>
</tr>
<tr>
<td>IV.12</td>
<td>Coding System for Extent of Disease</td>
<td>1 98</td>
<td>95</td>
</tr>
<tr>
<td>IV.13</td>
<td>Extent of Disease (EOD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A,B</td>
<td>Nonspecific/Two-Digit (1973-82)</td>
<td>2 99-100</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>Expanded (13 digit) Site-specific (1973-82)</td>
<td>13 101-113</td>
<td></td>
</tr>
<tr>
<td>D</td>
<td>SEER 4-digit Extent of Disease (1983-87)</td>
<td>4 114-117</td>
<td></td>
</tr>
<tr>
<td>IV.14</td>
<td>Field Not Used</td>
<td>10 128-137</td>
<td>98</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>V.01</th>
<th>Date Therapy Initiated</th>
<th>6 138-143</th>
<th>101</th>
</tr>
</thead>
<tbody>
<tr>
<td>V.02</td>
<td>Surgery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>Site-specific Surgery</td>
<td>2 144-145</td>
<td>103</td>
</tr>
<tr>
<td>B</td>
<td>Reason for No Cancer-Directed Surgery</td>
<td>1 146</td>
<td>106</td>
</tr>
<tr>
<td>V.03</td>
<td>Radiation</td>
<td>1 147</td>
<td>107</td>
</tr>
<tr>
<td>V.04</td>
<td>Radiation to the Brain and Central Nervous System</td>
<td>1 148</td>
<td>108</td>
</tr>
<tr>
<td>V.05</td>
<td>Radiation Sequence with Surgery</td>
<td>1 149</td>
<td>109</td>
</tr>
<tr>
<td>V.06</td>
<td>Chemotherapy</td>
<td>1 150</td>
<td>110</td>
</tr>
<tr>
<td>V.07</td>
<td>Endocrine (Hormone/Steroid) Therapy</td>
<td>1 151</td>
<td>111</td>
</tr>
<tr>
<td>V.08</td>
<td>Biological Response Modifiers</td>
<td>1 152</td>
<td>112</td>
</tr>
<tr>
<td>V.09</td>
<td>Other Cancer-directed Therapy</td>
<td>1 153</td>
<td>113</td>
</tr>
<tr>
<td>V.10</td>
<td>Field Not Used</td>
<td>18 154-171</td>
<td>114</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>VI.01</th>
<th>Date of Last Follow-Up or of Death</th>
<th>6 172-177</th>
<th>116</th>
</tr>
</thead>
<tbody>
<tr>
<td>VI.02</td>
<td>Vital Status</td>
<td>1 178</td>
<td>117</td>
</tr>
<tr>
<td>VI.03</td>
<td>ICD Code Revision Used for Cause of Death</td>
<td>1 179</td>
<td>118</td>
</tr>
<tr>
<td>VI.04</td>
<td>Underlying Cause of Death</td>
<td>5 180-184</td>
<td>119</td>
</tr>
<tr>
<td>VI.05</td>
<td>Type of Follow-Up</td>
<td>1 185</td>
<td>120</td>
</tr>
<tr>
<td>VI.06</td>
<td>Field Not Used</td>
<td>20 186-205</td>
<td>121</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>VII.01</th>
<th>Site/Type Interfield Review</th>
<th>1 206</th>
<th>123</th>
</tr>
</thead>
<tbody>
<tr>
<td>VII.02</td>
<td>Histology/Behavior Interfield Review</td>
<td>1 207</td>
<td>124</td>
</tr>
<tr>
<td>VII.03</td>
<td>Age/Site Histology Interfield Review</td>
<td>1 208</td>
<td>125</td>
</tr>
<tr>
<td>VII.04</td>
<td>Sequence Number/Diagnostic Confirmation Interfield Review</td>
<td>1 209</td>
<td>126</td>
</tr>
<tr>
<td>VII.05</td>
<td>Site/Histology/Laterality/Sequence Number Interrecord Review</td>
<td>1 210</td>
<td>127</td>
</tr>
</tbody>
</table>
### COMPUTER RECORD FORMAT

<table>
<thead>
<tr>
<th>Field</th>
<th>Section Number</th>
<th>Description</th>
<th>Char.</th>
<th>Length</th>
<th>Pos.</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>VII</td>
<td>06</td>
<td>Surgery Diagnostic Confirmation Interfield Review</td>
<td>1</td>
<td>211</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>VII</td>
<td>07</td>
<td>Type of Reporting Source Sequence Number Interfield Review</td>
<td>1</td>
<td>212</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>VII</td>
<td>08</td>
<td>Sequence Number, Ill-defined Site Interfield Review</td>
<td>1</td>
<td>213</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>VII</td>
<td>09</td>
<td>Leukemia or Lymphoma Diagnostic Confirmation Interfield Review</td>
<td>1</td>
<td>214</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>VII</td>
<td>10</td>
<td>Field Not Used</td>
<td>36</td>
<td>215-250</td>
<td>132</td>
<td></td>
</tr>
</tbody>
</table>

VII ADMINISTRATIVE CODES (cont'd)
INTRODUCTION AND GENERAL INSTRUCTIONS

Rules for Determining Multiple Primary Cancers (except for lymphatic and hematopoietic diseases): (cont'd)

2) Within each breast, combinations of ductal and lobular carcinoma occurring within two months of each other are considered a single primary and the histology coded according to the ICD-O, FT, 1988.

Note: If the ductal and lobular lesions for the female breast are reported to occur in different quadrants of the same breast, the appropriate site code is '174.9'. If the ductal lesion occurs in one breast and the lobular lesion occurs in the opposite breast, these are considered to be two primaries whether diagnosed within two months or not.

3) Some tumors have more than one histologic pattern. The most frequent combinations are listed in ICD-O, FT, 1988, under the term "mixed" in the alphabetic index. In addition combination terms such as "adenosquamous carcinoma (8560/3)" or "small cell-large cell carcinoma (8045/3)" are included. Any of these mixed histologies are to be considered one primary. Refer to the rule on "Compound Morphologic Diagnoses" (pg. xviii, International Classification of Diseases for Oncology, 1976 (ICD-O, 1976)) for rules on coding compound morphologic diagnoses or diagnoses including modifying adjectives which have different code numbers. For a diagnosis with more than one modifying adjective, consider this to be one primary and code to the highest histology.

b. Multiple lesions of different histologic types occurring in different sites are considered separate primaries whether occurring simultaneously or at different times.

6. If only one histologic type is reported and if both sides of a paired site are involved within two months of diagnosis, a determination must be made as to whether the patient has one or two independent primaries. If it is determined that there are two independent primaries, two records are to be submitted, each with the appropriate laterality and extent of disease information. If it is determined that there is only one primary, laterality should be coded according to the side in which the single primary originated and a single record submitted. If it is impossible to tell in which of the pair the single primary originated, laterality should be coded as a '4' and a single record submitted.

There are THREE EXCEPTIONS to this rule. Simultaneous bilateral involvement of the ovaries in which there is only a single histology is to be considered one primary and laterality is to be coded '4'. Bilateral retinoblastomas and bilateral Wilms's tumor are always considered single primaries (whether simultaneous or not), and laterality is coded as '4'.

9 THE SEER PROGRAM CODE MANUAL -- 1988 Revised May, 1988
INTRODUCTION AND GENERAL INSTRUCTIONS

Rules for Determining Multiple Primary Cancers (except for lymphatic and hematopoietic diseases): (cont'd)

7. Kaposi's sarcoma (9140/3) is reported only once. Kaposi's sarcoma is coded to the site in which it arises. If Kaposi's sarcoma arises in skin and another site simultaneously, code to skin (173.). If no primary site is stated, code to skin (173.).

Rules for Determining Multiple Primaries for Lymphatic and Hematopoietic Diseases:

The table on pages 11-35 is to be used to help determine multiple primaries of the lymphatic and hematopoietic diseases. Because of the rarity of subacute leukemias and aleukemias, they have been excluded from this table. Similarly, malignant myeloproliferative and immunoproliferative diseases, except Waldenstrom's disease, are not included. To use this table locate the first diagnosis in the left column of the table, then locate the second diagnosis in the other columns. If the second primary appears in the middle column, the two diagnoses are usually considered two separate primaries. If the second diagnosis appears in the right hand column, then the two diagnoses are usually considered one primary. Select the disease mentioned in the first column unless there is an indication in the right hand column to do otherwise. If the pathology report specifically states differently, use the pathology report. Consult your medical advisor or pathologist if questions remain.

For example,

1) a. first diagnosis: small cleaved cell, diffuse lymphoma
   b. second diagnosis: Hodgkin's disease, mixed cellularity

   This case would be considered two primaries.

2) a. first diagnosis: small cleaved cell, diffuse lymphoma
   b. second diagnosis: acute lymphocytic leukemia

   This case would be considered one primary.

RULES:

1. No topography (site) is to be considered in determining multiple primaries of lymphatic and hematopoietic diseases.

2. The interval between diagnoses is NOT to enter into the decision.

   Example: A lymphocytic lymphoma (M-9670/3) diagnosed in March, 1987 and an unspecified non-Hodgkin's lymphoma (M-9590/3) diagnosed in April, 1988 would be considered one primary, a lymphocytic lymphoma diagnosed in March, 1987 (the earlier diagnosis).
INTRODUCTION AND GENERAL INSTRUCTIONS

DETERMINATION OF SUBSEQUENT PRIMARIES OF LYMPHATIC (NODAL AND EXTRANODAL) AND HEMATOPOIETIC DISEASES

<table>
<thead>
<tr>
<th>First Primary</th>
<th>Presumably a Second Subsequent Primary</th>
<th>Presumably NOT a Subsequent Primary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multiple myeloma or plasmacytoma (9730,9731)</td>
<td>Non-Hodgkin's lymphoma except immunoblastic or large-cell lymphoma (9392-9394, 9670-9672,9676,9683, 9685-9686,9690-9697, 9702-9704)</td>
<td>Malignant lymphoma, NOS (9590,9591)</td>
</tr>
<tr>
<td>Hodgkin's disease (9650-9667)</td>
<td>Multiple myeloma or plasmacytoma (9730,9731)</td>
<td>Immuneblastic or large-cell lymphoma (9671,9680-9682, 9684,9698)</td>
</tr>
<tr>
<td>Burkitt's lymphoma (9687)</td>
<td>Plasma cell leukemia (9830)</td>
<td>Waldenstrom's macroglobulinemia (9761)</td>
</tr>
<tr>
<td>Mycosis fungoides or Sezary's disease (9700,9701)</td>
<td>Malignant histiocytosis or Letterer-Siwe's disease (9720,9722)</td>
<td></td>
</tr>
<tr>
<td>True histiocytic lymphoma (9723)</td>
<td>Mast cell tumor (9740,9741)</td>
<td></td>
</tr>
</tbody>
</table>
| Leukemia except plasma cell (9800-9825, 9840-9940) | *Occasionally multiple myeloma develops an immunoblastic or large cell lymphoma phase. This is to be considered one primary, multiple myeloma. Consult your medical advisor or pathologist if questions remain.*

INTRODUCTION AND GENERAL INSTRUCTIONS

DETERMINATION OF SUBSEQUENT PRIMARIES OF LYMPHATIC (NODAL AND EXTRANODAL) AND HEMATOPOIETIC DISEASES

<table>
<thead>
<tr>
<th>First Primary</th>
<th>Presumably a Second Subsequent Primary</th>
<th>Presumably NOT a Subsequent Primary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mast cell tumor (9740,9741)</td>
<td>Non-Hodgkin's lymphoma (9590-9594,9670-9687, 9690-9698,9702-9704)</td>
<td>Mast cell tumor (9740,9741)</td>
</tr>
<tr>
<td>Hodgkin's disease (9650-9667)</td>
<td>Leukemia, NOS (9800)</td>
<td></td>
</tr>
<tr>
<td>Mycosis fungoides or Sezary's disease (9700,9701)</td>
<td>Acute leukemia, NOS (9801)</td>
<td></td>
</tr>
<tr>
<td>Malignant histiocytosis or Letterer-Siwe's disease (9720,9722)</td>
<td>Chronic leukemia, NOS (9803)</td>
<td></td>
</tr>
<tr>
<td>True histiocytic lymphoma (9723)</td>
<td>Monocytic leukemia (9890-9893)</td>
<td></td>
</tr>
<tr>
<td>Multiple myeloma or plasmacytoma (9730,9731)</td>
<td>Mast cell leukemia (9900)</td>
<td></td>
</tr>
<tr>
<td>Non-lymphocytic leukemias (9840-9842,9860-9880, 9910)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic lymphocytic leukemia (9823)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma cell leukemia (9830)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphosarcoma cell leukemia (9850)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myeloid sarcoma (9930)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**DETERMINATION OF SUBSEQUENT PRIMARIES OF**
**LYMPHATIC (NODAL AND EXTRANODAL) AND HEMATOPOIETIC DISEASES**

<table>
<thead>
<tr>
<th>First Primary</th>
<th>Presumably a Second Subsequent Primary</th>
<th>Presumably NOT a Subsequent Primary (only One Primary)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mast cell tumor (9740-9741)</td>
<td>Acute panmyelosis (9931)</td>
<td></td>
</tr>
<tr>
<td>(cont'd)</td>
<td>Acute myelofibrosis (9932)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hairy cell leukemia (9940)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Waldenstrom's macroglobulinemia (9761)</td>
<td></td>
</tr>
</tbody>
</table>

---

This table outlines the determination of subsequent primaries of lymphatic (nodal and extranodal) and hematopoietic diseases, distinguishing between those that are presumably or presumably not a second primary, and those that may indicate only one primary occurrence.
INTRODUCTION AND GENERAL INSTRUCTIONS

DETERMINATION OF SUBSEQUENT PRIMARIES OF LYMPHATIC (NODAL AND EXTRANODAL) AND HEMATOPOIETIC DISEASES

<table>
<thead>
<tr>
<th>First Primary</th>
<th>Presumably a Second</th>
<th>Presumably NOT a Subsequent Primary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presumably a Second</td>
<td></td>
<td>Presumably NOT a</td>
</tr>
<tr>
<td>Presumably NOT a</td>
<td></td>
<td>Subsequent Primary</td>
</tr>
<tr>
<td>(only One Primary)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Waldenstrom's macroglobulinemia (9761) | Non-Hodgkin's lymphoma except immunoblastic or large cell lymphoma (9593-9594, 9673-9676, 9683, 9685-9686, 9690-9697, 9702-9704) | Malignant lymphoma, NOS (9590, 9591) |
|                                       | Lyphosarcoma (9592) | Immunoblastic or large cell lymphoma (9671, 9680-9682, 9684-9698) |
|                                       | Hodgkin's disease (9650-9667) |                                      |
|                                       | Burkitt's lymphoma (9687) | Malignant lymphoma, lymphocytic (9670, 9672) |
|                                       | Mycosis fungoides or Sezary's disease (9700, 9701) | Multiple myeloma or plasmacytoma (9730, 9731) |
|                                       | Malignant histiocytosis or Letterer-Siwe's disease (9720, 9722) | Plasma cell leukemia (9830) |
|                                       | True histiocytic lymphoma (9723) | Waldenstrom's macroglobulinemia (9761) |
|                                       | Mast cell tumor (9740, 9741) |                                      |
|                                       | Leukemia except plasma cell (9800-9825, 9840-9940) |                                      |

### SEER CODE SUMMARY

Section IV, Fields 01-05

<table>
<thead>
<tr>
<th>Section, Field Number</th>
<th>Code</th>
<th>Description</th>
<th>Character Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV. Description of This Neoplasm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV.01</td>
<td></td>
<td>Date of Diagnosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Month</td>
<td></td>
<td>72-73</td>
</tr>
<tr>
<td></td>
<td>01-12 Month</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>99</td>
<td>Unknown</td>
<td>74-77</td>
</tr>
<tr>
<td></td>
<td>Year</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>All four digits of year</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV.02</td>
<td></td>
<td>Sequence Number</td>
<td>78-79</td>
</tr>
<tr>
<td></td>
<td>00</td>
<td>One primary only</td>
<td></td>
</tr>
<tr>
<td></td>
<td>01</td>
<td>First of two or more primaries</td>
<td></td>
</tr>
<tr>
<td></td>
<td>02</td>
<td>Second of two or more primaries</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Actual number of this primary)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>Tenth of ten or more primaries</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11</td>
<td>Eleventh of eleven or more primaries</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Unspecified sequence number</td>
<td></td>
</tr>
<tr>
<td>IV.03</td>
<td></td>
<td>Primary Site</td>
<td>80-82</td>
</tr>
<tr>
<td>IV.04</td>
<td></td>
<td>Field Not Used</td>
<td>83</td>
</tr>
<tr>
<td>IV.05</td>
<td></td>
<td>Laterality at Diagnosis</td>
<td>84</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>Not a paired site</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>Right: origin of primary</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>Left: origin of primary</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>Only one side involved, right or left origin</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>unspecified</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>Bilateral involvement, lateral origin</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>unknown: stated to be single primary</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Both ovaries involved simultaneously</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>single histology</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bilateral retinoblastomas</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bilateral Wilms's tumors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>Paired site, but no information concerning</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>laterality; midline tumor</td>
<td></td>
</tr>
</tbody>
</table>
### Section IV, Fields 06-07

#### Character Number

<table>
<thead>
<tr>
<th>Character Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV.06 Morphology</td>
<td>85-91</td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Field Number</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV.06.A</td>
<td>Histologic Type</td>
<td>85-88</td>
</tr>
<tr>
<td>IV.06.B</td>
<td>Behavior code</td>
<td>89</td>
</tr>
<tr>
<td>IV.06.C</td>
<td>Grade, Differentiation, or Cell Indicator</td>
<td>90</td>
</tr>
</tbody>
</table>

**IV.07 Tumor Markers**

<table>
<thead>
<tr>
<th>Field Number</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV.07.A</td>
<td>Tumor Marker 1</td>
<td>91</td>
</tr>
</tbody>
</table>

*For Breast Cases Only*

**Estrogen Receptor**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None done</td>
</tr>
<tr>
<td>1</td>
<td>Positive</td>
</tr>
<tr>
<td>2</td>
<td>Negative</td>
</tr>
<tr>
<td>3</td>
<td>Borderline; undetermined whether positive or negative</td>
</tr>
<tr>
<td>8</td>
<td>Ordered, but results not in chart</td>
</tr>
<tr>
<td>9</td>
<td>Unknown or no information</td>
</tr>
</tbody>
</table>

*For All Other Cases*

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

**IV.07.B Tumor Marker 2**

*For Breast Cases Only*

**Progesterone Receptor**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None done</td>
</tr>
<tr>
<td>1</td>
<td>Positive</td>
</tr>
<tr>
<td>2</td>
<td>Negative</td>
</tr>
<tr>
<td>3</td>
<td>Borderline; undetermined whether positive or negative</td>
</tr>
<tr>
<td>8</td>
<td>Ordered, but results not in chart</td>
</tr>
<tr>
<td>9</td>
<td>Unknown or no information</td>
</tr>
</tbody>
</table>

*For All Other Cases*

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>
### SEER CODE SUMMARY
Section IV, Fields 08-14

<table>
<thead>
<tr>
<th>Field Number</th>
<th>Code</th>
<th>Description</th>
<th>Character Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV.08</td>
<td></td>
<td>Diagnostic Confirmation</td>
<td>91</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>Positive histology</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>Positive exfoliative cytology, no positive histology</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>Positive microscopic confirmation, method not specified</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>Positive laboratory test/marker study</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>Direct visualization without microscopic confirmation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>Radiography and other imaging techniques without microscopic confirmation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>Clinical diagnosis only (other than 5, 6, or 7)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>Unknown whether or not microscopically confirmed</td>
<td></td>
</tr>
<tr>
<td>IV.09</td>
<td></td>
<td>Field Not Used</td>
<td>94</td>
</tr>
<tr>
<td>IV.10</td>
<td></td>
<td>Diagnostic Procedures (1973-87)</td>
<td>95-96</td>
</tr>
<tr>
<td></td>
<td></td>
<td>See site-specific detail in Appendix D.</td>
<td></td>
</tr>
<tr>
<td>IV.11</td>
<td></td>
<td>Field Not Used</td>
<td>97</td>
</tr>
<tr>
<td>IV.12</td>
<td></td>
<td>Coding System for Extent of Disease</td>
<td>98</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>SEER Nonspecific (1973-82)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>SEER Two-Digit Site-Specific (1973-82)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>SEER Expanded (13-digit) Site-Specific (1973-82)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>SEER 4-digit Extent of Disease (1983-87)</td>
<td></td>
</tr>
<tr>
<td>IV.13</td>
<td></td>
<td>Extent of Disease</td>
<td></td>
</tr>
<tr>
<td>IV.13.C</td>
<td></td>
<td>SEER Expanded (13-digit) Site-Specific (1973-82)</td>
<td>101-113</td>
</tr>
<tr>
<td>IV.13.D</td>
<td></td>
<td>SEER 4-digit Extent of Disease (1983-87)</td>
<td>114-117</td>
</tr>
<tr>
<td>IV.14</td>
<td></td>
<td>Field Not Used</td>
<td>128-137</td>
</tr>
</tbody>
</table>

### V. First Course of Cancer-Directed Therapy

#### V.01 Date Therapy Initiated

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>000000</td>
<td>No cancer-directed therapy</td>
<td>138-139</td>
</tr>
<tr>
<td>999999</td>
<td>Unknown if any cancer-directed therapy was administered</td>
<td></td>
</tr>
</tbody>
</table>

- **Month**
  - 01-12 Month
  - 99 Unknown

- **Year**
  - All four digits of year
  - 9999 Unknown

#### V.02 Surgery

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
</table>

- **V.02.A Site-Specific Surgery**
  - See two-digit code for surgery detail in Appendix C of this manual.

- **V.02.B Reason for No Cancer-Directed Surgery**
  - 0 Cancer-directed surgery performed
  - 1 Cancer-directed surgery not recommended
  - 2 Contraindicated due to other conditions; Autopsy Only case
  - 6 Unknown reason for no cancer-directed surgery
  - 7 Patient or patient's guardian refused
  - 8 Recommended, unknown if done
  - 9 Unknown if cancer-directed surgery performed; Death Certificate Only case

#### V.03 Radiation

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None</td>
</tr>
<tr>
<td>1</td>
<td>Beam radiation</td>
</tr>
<tr>
<td>2</td>
<td>Radioactive implants</td>
</tr>
<tr>
<td>3</td>
<td>Radioisotopes</td>
</tr>
<tr>
<td>4</td>
<td>Combination of 1 with 2 or 3</td>
</tr>
<tr>
<td>5</td>
<td>Radiation, NOS -- method or source not specified</td>
</tr>
<tr>
<td>7</td>
<td>Patient or patient's guardian refused</td>
</tr>
<tr>
<td>8</td>
<td>Radiation recommended, unknown if administered</td>
</tr>
<tr>
<td>9</td>
<td>Unknown</td>
</tr>
</tbody>
</table>
TYPE OF REPORTING SOURCE

Section II, Field 01

---

Code:

Type of Reporting Source

1. Hospital Inpatient/Outpatient or Clinic
3. Laboratory (Hospital or Private)
4. Private Medical Practitioner (LMD)
5. Nursing/Convalescent Home/Hospice
6. Autopsy Only
7. Death Certificate Only

The hospital record for an inpatient with a cancer diagnosis (before death) takes precedence over other types of reports.

Code '6', Autopsy Only, means that the cancer was not diagnosed even as a clinical diagnosis while the patient was alive. If the patient was an inpatient with another admitting diagnosis and an autopsy disclosed the cancer for the first time, code '6' is proper. Autopsy findings take precedence over death certificate information, i.e., code '6' takes precedence over code '7'. However, a clinical diagnosis of cancer at any of the sources coded '1'-'5' has priority over confirmation at autopsy.

For Autopsy Only cases:
1. Date of Diagnosis (IV.01) must be the date of death.
2. For breast cases diagnosed on or after January 1, 1990, code both Tumor Markers (IV.07A,IV.07B) to '0'; for all other cases code '9'.
3. Code Date Therapy Initiated (V.01) to '000000'.
4. For lung and leukemia diagnoses, code Radiation to the Brain and Central Nervous System (V.04) to '0'; for all other cases code '9'.
5. Code Reason for No Cancer-directed Surgery (V.02B) to '2'.
6. Code all remaining treatment fields (V.02A,V.03,V.05-V.09) to zero.

Code '7', Death Certificate Only (including Coroners' case), is used only when "follow-back" activities have produced no other medical reports -- the death certificate is truly the only source of information. Often a case is reported first via the death certificate, but later registry action yields missing or additional medical reports. Such additional reports take precedence.

For Death Certificate Cases:
1. Date of Diagnosis (IV.01) must be the date of death.
2. Code both Tumor Markers (IV.07A,IV.07B) to '9'.
3. Code Diagnostic Confirmation (IV.08) to '9'.
4. Code Date Therapy Initiated (V.01) to '999999'.
5. Code Site-specific Surgery (V.02A) to '09'.
6. Code Reason for No Cancer-directed Surgery (V.02B) to '9'.
7. Code Radiation Sequence with Surgery (V.05) to '0'.
8. Code all remaining treatment fields (V.03,V.04,V.06-V.09) to '9'.

---

Section II, Field 02

Blanks should be submitted in this field.
GRADE, DIFFERENTIATION, OR CELL INDICATOR

Section IV, Field 00.C

The grading or differentiation, or for lymphomas and leukemias, designation of T-cell, B-cell, and null cell is described on page 25 of ICD-O, FT, 1988.

Grade, differentiation

If a diagnosis indicates two different degrees of grade or differentiation (e.g., "well and poorly differentiated"; or "grade II-III", or "well differentiated grade II"), code to the higher grade code (Rule 10, page xxiii in ICD-O, 1976).

Code the degree of differentiation or grade stated in the final pathologic diagnosis only.

For example:

Microscopic Description: Moderately differentiated squamous cell carcinoma with poorly differentiated areas
Final Pathologic Diagnosis: Moderately differentiated squamous cell carcinoma

Code to the final diagnosis: Moderately differentiated '2'.

Usually there will be no statement as to grade for in situ lesions. However, if a grade is stated, it should be coded.

When there is variation in the usual terms for degree of differentiation, code to the higher grade as specified below:

<table>
<thead>
<tr>
<th>Term</th>
<th>Grade</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low grade</td>
<td>I-II</td>
<td>2</td>
</tr>
<tr>
<td>Medium grade</td>
<td>II-III</td>
<td>3</td>
</tr>
<tr>
<td>High grade</td>
<td>III-IV</td>
<td>4</td>
</tr>
<tr>
<td>Partially well differentiated</td>
<td>I-II</td>
<td>2</td>
</tr>
<tr>
<td>Moderately undifferentiated</td>
<td>III</td>
<td>3</td>
</tr>
<tr>
<td>Relatively undifferentiated</td>
<td>III</td>
<td>3</td>
</tr>
</tbody>
</table>

Note: Where there is no tissue diagnosis, it may still be possible to establish the grade of a tumor through Magnetic Resonance Imaging (MRI) or Positron Emission Tomography (PET). In particular, it is now possible to grade brain tumors by this method. Thus, if there is no tissue diagnosis, but there is a grade/differentiation available from an MRI or PET report, code grade based on those reports. If there is a tissue diagnosis, grade should be from the pathology report only.
According to the *Manual for Staging Cancer, Third Edition*, from the American Joint Committee on Cancer, grade of tumor is required for the following sites to be staged:

- 158.0-158.9 Retroperitoneum and peritoneum
- 164.1-164.9 Heart and mediastinum
- 170.0-170.9 Bone
- 171.0-171.9 Connective, subcutaneous and other soft tissue
- 185.9 Prostate gland
- 191.0-191.9 Brain
- 192.1 Cerebral meninges

Grade coding for prostate cases using Gleason's score or pattern:

1. If Gleason's score (2-10) is given, code as follows:

<table>
<thead>
<tr>
<th>Gleason's score</th>
<th>Grading</th>
</tr>
</thead>
<tbody>
<tr>
<td>2, 3, 4</td>
<td>I Well Differentiated</td>
</tr>
<tr>
<td>5, 6, 7</td>
<td>II Moderately Differentiated</td>
</tr>
<tr>
<td>8, 9, 10</td>
<td>III Poorly Differentiated</td>
</tr>
</tbody>
</table>

2. If Gleason's pattern (1-5) is given, code as follows:

<table>
<thead>
<tr>
<th>Gleason's pattern</th>
<th>Grading</th>
</tr>
</thead>
<tbody>
<tr>
<td>1, 2</td>
<td>I Well Differentiated</td>
</tr>
<tr>
<td>3</td>
<td>II Moderately Differentiated</td>
</tr>
<tr>
<td>4, 5</td>
<td>III Poorly Differentiated</td>
</tr>
</tbody>
</table>

For lymphomas and leukemias, designation of T-cell, B-cell, and null cell

Code the final pathologic diagnosis of T-cell, B-cell or null cell whether or not marker studies are documented in the patient record. (See page 24 of ICD-O, FT, 1988.)

For lymphomas and leukemias, information on T-cell, B-cell or null cell has precedence over information on grading or differentiation.
Discussion:

Tumor Markers are prognostic indicators. SEER collects only estrogen and progesterone receptors for breast cancer as of January 1, diagnoses.
TUMOR MARKER 1

Section IV, Field 07.A

Code:

Tumor Marker 1

For Breast Cases Only

Estrogen Receptor
0 None done
1 Positive
2 Negative
3 Borderline; undetermined whether positive or negative
8 Ordered, but results not in chart
9 Unknown or no information

For All Other Cases

9 Not applicable

For breast cases only diagnosed on or after January 1, 1990:
1. Code '0' for all "Autopsy Only" cases;
2. Code '9' for all "Death Certificate Only" cases;
3. Code '0'-'9' for all other cases.

For all sites except breast diagnosed on or after January 1, 1990, code '9'.

For all diagnoses before January 1, 1990, code '9'.

89.1 THE SEER PROGRAM CODE MANUAL -- 1988 Revised January, 1990
TUMOR MARKER 2

Section IV, Field 07.B

Code:

Tumor Marker 2

For Breast Cases Only

Progestosterone Receptor
0 None done
1 Positive
2 Negative
3 Borderline; undetermined whether positive or negative
8 Ordered, but results not in chart
9 Unknown or no information

For All Other Cases

9 Not applicable

For breast diagnoses only on or after January 1, 1990:
1. Code '0' for all "Autopsy Only" cases;
2. Code '9' for all "Death Certificate Only" cases;
3. Code '0'-'9' for all other cases.

For all sites except breast diagnosed on or after January 1, 1990, code '9'.

For all diagnoses before January 1, 1990, code '9'.

Diagnostic Confirmation indicates whether at any time during the patient's medical history there was microscopic confirmation of the morphology of this cancer. It indicates not only the fact of microscopic confirmation but the nature of the best evidence available. Thus, this is a priority series with code '1' taking precedence. Each number takes priority over all higher numbers.

Code:

Diagnostic Confirmation

Microscopically Confirmed

1 Positive histology
2 Positive exfoliative cytology, no positive histology
4 Positive microscopic confirmation, method not specified

Not Microscopically Confirmed

5 Positive laboratory test/marker study
6 Direct visualization without microscopic confirmation
7 Radiography and other imaging techniques without microscopic confirmation
8 Clinical diagnosis only (other than 5, 6, or 7)

Confirmation unknown

9 Unknown whether or not microscopically confirmed

Specific:

Code 1: Microscopic diagnoses based upon tissue specimens from biopsy, frozen section, surgery, autopsy, or D and C. Positive hematologic findings relative to leukemia are also included. Bone marrow specimens (including aspiration biopsies) are coded as '1'.

Code 2: Cytologic diagnoses based on microscopic examination of cells as contrasted with tissues. Included are smears from sputum, bronchial brushings, bronchial washings, tracheal washings, prostatic secretions, breast secretions, gastric fluid, spinal fluid, peritoneal fluid, pleural fluid, and urinary sediment. Cervical and vaginal smears are common examples. Also included are diagnoses based upon paraffin block specimens from concentrated spinal, pleural, or peritoneal fluid.

Code 4: Diagnoses stated to be microscopically confirmed but with no detailed information on method.

Code 5: Clinical diagnosis of cancer based on certain laboratory tests or marker studies which are clinically diagnostic for cancer. Examples are the presence of fetal alpha protein for liver cancer and an abnormal electrophoretic spike for multiple myeloma and Waldenstrom's macroglobulinemia.
FIRST COURSE OF CANCER-DIRECTED THERAPY

Section V, Introduction

For the SEER Program the concept of definitive treatment is limited to procedures directed toward cancer tissues whether of the primary site or metastases. If a specific therapy normally affects, controls, changes, removes, or destroys cancer tissue, it is classified as definitive treatment even if it cannot be considered curative for a particular patient in view of the extent of disease, incompleteness of treatment, lack of apparent response, size of dose, operative mortality, or other criteria. The first course of cancer-directed therapy may begin any time at or after diagnosis.

Definition of "First Course" for all Malignancies Except Leukemias:

For all cases, the first course of therapy includes all cancer-directed treatment administered to the patient within four months after the initiation of therapy. All modalities of treatment are included regardless of sequence or the degree of completion of any component method.

Exceptions:

1. If it is documented that the planned first course of therapy continued beyond or began after four months of initiation, include all as first course.

2. Should there be a change of therapy due to apparent failure of the original planned and administered treatment or because of progression of the disease, the later therapy should be EXCLUDED from the first course and considered part of a SECOND course of therapy.

Definitions of "First Course" for Leukemias:

The basic time period is two months after the date of initiation of therapy. When precise information permits, the first course of definitive treatment is to be related to the first "remission" as follows -- even if in violation of the two-month rule:

A. If a remission, complete or partial, is achieved during the first course of therapy for the leukemic process, include:

1. All definitive therapy considered as "remission-inducing" for the first remission, and

2. All definitive therapy considered as "remission-maintaining" for the first remission, i.e., irradiation to the central nervous system.

3. Disregard all treatment administered to the patient after the lapse of the first remission.

B. If no remission is attained during the first course of therapy, use the two-month rule.
Section V, Introduction

FIRST COURSE OF CANCER-DIRECTED THERAPY (cont'd)

No Cancer-Directed Therapy:

"Cancer tissue" means proliferating malignant cells or an area of active production of malignant cells such as adjacent tissues or distant sites. In some instances, malignant cells are found in tissues where they did not originate and where they do not reproduce, such as malignant cells found at thoracentesis or paracentesis. A procedure removing malignant cells but not treating a site of proliferation of such cells is NOT to be considered cancer therapy for the purpose of this program.

If patient receives ONLY symptomatic or supportive therapy, this is classified as "no cancer-directed therapy."

The term "palliative" is normally used in two senses: (a) as meaning non-curative and (b) as meaning the alleviation of symptoms. Thus, some treatments termed palliative fall within the definition of cancer-directed treatment and some are excluded as treating the patient but not the cancer.

Autopsy Only and Death Certificate Only Cases:

For Autopsy Only cases:
1. Code Date Therapy Initiated (V.01) to '000000'.
2. For lung and leukemia diagnoses, code Radiation to the Brain and Central Nervous System (V.04) to '0'; for all other cases code '9'.
3. Code Reason for No Cancer-directed Surgery (V.02B) to '2'.
4. Code all remaining treatment fields to zero.

For Death Certificate Only cases:
1. Code Date Therapy Initiated (V.01) to '999999'.
2. Code Site-specific Surgery (V.02A) to '09'.
3. Code Reason for No Cancer-directed Surgery (V.02B) to '9'.
4. Code Radiation Sequence with Surgery (V.05) to '0'.
5. Code all remaining treatment fields to '9'.

100 THE SEER PROGRAM CODE MANUAL -- 1988 March, 1988
GENERAL INSTRUCTIONS FOR CODING SITE-SPECIFIC SURGERY

The site-specific surgery scheme is composed of a two-digit code for all sites. Individual schemes exist in Appendix C for these sites:

<table>
<thead>
<tr>
<th>ICD-O</th>
<th>Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>140.0-149.9</td>
<td>Oral Cavity</td>
</tr>
<tr>
<td>151.0-151.9</td>
<td>Stomach</td>
</tr>
<tr>
<td>153.0-153.9</td>
<td>Colon</td>
</tr>
<tr>
<td>154.0-154.1</td>
<td>Rectosigmoid, Rectum</td>
</tr>
<tr>
<td>157.0-157.9</td>
<td>Pancreas</td>
</tr>
<tr>
<td>161.0-161.9</td>
<td>Larynx</td>
</tr>
<tr>
<td>162.2-162.9</td>
<td>Bronchus and Lung</td>
</tr>
<tr>
<td>169.2</td>
<td>Spleen</td>
</tr>
<tr>
<td>170.0-170.9</td>
<td>Connective tissue</td>
</tr>
<tr>
<td>171.0-171.9</td>
<td>Bone</td>
</tr>
<tr>
<td>173.0-173.9</td>
<td>Skin</td>
</tr>
<tr>
<td>174.0-174.9, 175.9</td>
<td>Breast</td>
</tr>
<tr>
<td>180.0-180.9</td>
<td>Cervix Uteri</td>
</tr>
<tr>
<td>182.0-182.8</td>
<td>Corpus Uteri</td>
</tr>
<tr>
<td>183.0</td>
<td>Ovary</td>
</tr>
<tr>
<td>185.9</td>
<td>Prostate</td>
</tr>
<tr>
<td>186.0-186.9</td>
<td>Testis</td>
</tr>
<tr>
<td>188.0-188.9</td>
<td>Bladder</td>
</tr>
<tr>
<td>189.0-189.2</td>
<td>Kidney, Renal Pelvis, Ureter</td>
</tr>
<tr>
<td>193.9</td>
<td>Thyroid</td>
</tr>
<tr>
<td>196.0-196.9</td>
<td>Lymph nodes</td>
</tr>
</tbody>
</table>

All other sites are coded to the general scheme in Appendix C.

Once it is determined that cancer-directed surgery was performed, use the best information in the operative/pathology reports to determine the operative procedure. Do NOT depend on the name of the procedure since it may be incomplete.

If the operative report is unclear as to what was excised or if there is a discrepancy between the operative and pathology reports, use the pathology report, unless there is reason to doubt its accuracy.

If a surgical procedure removes the remaining portion of an organ which had been partially resected previously for any condition, code as total removal of the organ. If none of the primary organ remains, the code should indicate that this is the case.
GENERAL INSTRUCTIONS FOR CODING SITE-SPECIFIC SURGERY (cont'd)

For example:
1. Resection of a stomach which had been partially excised previously is coded as total removal of stomach.
2. Removal of a cervical stump is coded as total removal of uterus.
3. Lobectomy of a lung with a previous wedge resection is coded as total removal of lobe.

For purposes of this program a lymph node dissection is defined as any lymph node dissection done within the first course of cancer-directed therapy. Any lymph node dissection done as a separate procedure within the first course of cancer-directed therapy is to be coded.

In order to code the removal of lymph nodes as "surgery with lymph node dissection", a minimum of four lymph nodes must be removed.

If an excisional biopsy is followed by "re-excision" or "wide excision" within the first course of cancer-directed therapy, include that later information in coding site-specific surgery.

If multiple primaries are excised at the same time, code the appropriate surgery for each site. For example: 1) if a total abdominal hysterectomy was done for a patient with two primaries, one of the cervix and one of the endometrium, code each as having had a total abdominal hysterectomy. 2) If a total colectomy was done for a patient with multiple primaries in several segments of the colon, code total colectomy for each of the primary segments.

Surgery for extranodal lymphomas should be coded using the scheme for the extranodal site. For example: a lymphoma of the stomach is to be coded using the scheme for stomach.

Ignore surgical approach in coding procedures.

Ignore the use of laser if used only for the initial incision.

Surgical procedures performed solely for the purpose of establishing a diagnosis/stage or for the relief of symptoms are to be coded in the Site-specific Surgery field using codes '01'- '97' but are not considered cancer-directed surgery.

Procedures such as brushings, washings, and aspiration of cells as well as hematologic findings (peripheral blood smears) are not surgical procedures.
GENERAL INSTRUCTIONS FOR CODING SITE-SPECIFIC SURGERY (cont'd)

Examples of exploratory surgery are:
- Celiotomy
- Laparotomy
- Cystotomy
- Nephrotyom
- Gastroscopy
- Thoracotomy

Examples of bypass surgery are:
- Colostomy
- Nephrostomy
- Esophagostomy
- Tracheostomy
- Gastrosotmy
- Urethrostomy

Priority of Codes

In the Site-specific Surgery code schemes, except where otherwise noted, the following priorities hold:

1. Codes '10'-'90' over codes '00'-'09'.
2. Codes '10'-'78' over codes '80'-'90'.
3. In the range '10'-'78' the higher code has priority.
4. Codes '01'-'07' over code '09'.
5. In the range '01'-'09' the higher code has priority.
6. Codes '01'- '07' and '09' cannot be used in combination with codes '10'- '90'.
7. Surgery of primary not included in any category should be coded '90'.
8. Codes '01'-'06' have priority over code '07'.

Reconstructive Surgery

Second digit is to be coded '8' when reconstructive surgery of the primary site is done as part of the planned first course of therapy.

Examples of reconstructive surgery are:
- Ileal pouch-anal anastomosis for colon
- Facial reconstruction for head and neck tumors
- Breast reconstruction

The following examples are not considered reconstructive surgery:
- Colostomy
- Skin grafting

REASON FOR NO CANCER-DIRECTED SURGERY
Section V, Field 02.B

Code:

Reason for No Cancer-directed Surgery

0  Cancer-directed surgery performed
1  Cancer-directed surgery not recommended
2  Contraindicated due to other conditions; Autopsy Only case
6  Unknown reason for no cancer-directed surgery
7  Patient or patient's guardian refused
8  Recommended, unknown if done
9  Unknown if cancer-directed surgery performed; Death Certificate Only case

If the Site-specific Surgery is coded '00'- '09', then code the reason using codes '1'- '9'.

If the site-specific surgery is coded '10'- '99', then code the Reason for No Cancer-directed Surgery as '0'.

RADIATION
Section V, Field 03
=================================================================================================

Code:

Radiation

0  None
1  Beam radiation
2  Radioactive implants
3  Radioisotopes
4  Combination of 1 with 2 or 3
5  Radiation, NOS -- method or source not specified
7  Patient or patient's guardian refused radiation therapy
8  Radiation recommended, unknown if administered
9  Unknown

Code '1' for beam radiation directed to cancer tissue regardless of source of radiation. Included is treatment via:
X-ray
Cobalt
Linear accelerator
Neutron beam
Betatron
Spray radiation
Stereotactic radiosurgery such as gamma knife and proton beam.

Code '2' for all interstitial implants, molds, seeds, needles, or intracavitary applicators of radioactive material such as cesium, radium, radon, or radioactive gold.

Code '3' for internal use of radioactive isotopes, such as I-131 or P-32, when given orally, intracavitarily, or by intravenous injection.

For lung and leukemia cases only, code radiation to brain and central nervous system in the Radiation to the Brain and Central Nervous System field.

For all cases except lung and leukemia, code radiation to brain and central nervous system in this field.
RADIATION TO THE BRAIN AND CENTRAL NERVOUS SYSTEM
Section V, Field 04
=====================================================================

Code:

Radiation to the Brain and/or Central Nervous System

For Lung and Leukemia Cases Only

0 No radiation to the brain and/or central nervous system
1 Radiation
7 Patient or patient's guardian refused
8 Radiation recommended, unknown if administered
9 Unknown

For All Other Cases

9 Not applicable

For lung and leukemia diagnoses only:
1. code '0' for all "Autopsy Only" cases;
2. code '9' for all "Death Certificate Only" cases;
3. code '0'-'9' for all other cases.

Radiation should be coded whether or not there are known metastases to the brain or central nervous system.

For all sites except lung and leukemia diagnoses, code '9'.
APPENDIX C
SITE-SPECIFIC SURGERY CODES

PANCREAS

157.0-157.9

Code:

No Cancer-Directed Surgery/Unknown

00 No surgical procedure
01 Incisional, needle, or aspiration biopsy of other than primary site
02 Incisional, needle, or aspiration biopsy of primary site
03 Exploratory ONLY (no biopsy)
04 Bypass surgery, -ostomy ONLY (no biopsy)
05 Exploratory ONLY AND incisional, needle or aspiration biopsy of primary site or other sites
06 Bypass surgery, -ostomy ONLY AND incisional, needle or aspiration biopsy of primary site or other sites
07 Non-cancer directed surgery, NOS
09 Unknown if surgery done

Type of Cancer-Directed Surgery

10 Local or partial surgical excision of pancreas
20 Total pancreatectomy WITH/WITHOUT splenectomy
30 Subtotal gastrectomy, duodenectomy with complete or partial pancreatectomy WITH/WITHOUT splenectomy (Whipple's operation)
40 Radical regional (partial) pancreatectomy with lymph node dissection and adjacent soft tissue resection
50 Pancreatectomy, NOS
80 Surgery of regional and/or distant site(s)/node(s) ONLY
90 Surgery, NOS

NOTE: Codes '10'-'90' have priority over codes '00'-'09'.
Codes '10'-'78' have priority over codes '30'-'90'.
Surgery of primary not included in any category should be coded '90'.
In the range '10'-'78', the higher code has priority.
Codes '01'-'07' have priority over code '09'.
In the range '01'-'06', the higher code has priority.
Codes '01'-'07' and '09' cannot be used in combination with codes '10'-'90'.
Codes '01'-'06' have priority over code '07'.
Second digit is to be coded '8' when reconstructive surgery of the primary site is done as part of the planned first course of therapy.
APPENDIX C
SITE-SPECIFIC SURGERY CODES

SKIN
173.0-173.9

Code:

No Cancer-Directed Surgery/Unknown

00 No surgical procedure
01 Incisional, needle, or aspiration biopsy of other than primary site
02 Incisional, needle, or aspiration biopsy of primary site
03 Exploratory ONLY (no biopsy)
04 Bypass surgery, -ostomy ONLY (no biopsy)
05 Exploratory ONLY AND incisional, needle or aspiration biopsy of primary site or other sites
06 Bypass surgery, -ostomy ONLY AND incisional, needle or aspiration biopsy of primary site or other sites
07 Non-cancer directed surgery, NOS
09 Unknown if surgery done

Type of Cancer-Directed Surgery

10 Local cancer destruction WITHOUT pathology specimen (includes laser surgery, cryosurgery, fulguration, or electrocauterization)
20 Simple excision/excisional biopsy; shave biopsy; local surgical excision; wedge resection; laser surgery WITH pathology specimen; excision, NOS
30 Shave/punch biopsy/biopsy, NOS followed by excision of lesion (not a wide excision)
40 Wide/re-excision or minor (local) amputation (includes digits, ear, eyelid, lip, nose) WITHOUT lymph node dissection
45 Radical excision WITHOUT lymph node dissection
50 Codes 10-45 WITH lymph node dissection
60 Amputation (other than code 40) WITHOUT lymph node dissection; amputation, NOS
70 Amputation (other than in code 40) WITH lymph node dissection
80 Surgery of regional and/or distant site(s)/node(s) ONLY
90 Surgery, NOS

APPENDIX C
SITE-SPECIFIC SURGERY CODES

SKIN (cont'd)

NOTE: Codes 10'-90' have priority over codes 00'-09'.
Codes 10'-78' have priority over codes 80'-90'.
Surgery of primary not included in any category should be coded '99'.
In the range 10'-78', the higher code has priority.
Codes 01'-02' have priority over code 09'.
In the range 01'-06', the higher code has priority.
Codes 01'-07' and 09' cannot be used in combination with codes 10'-90'.
Codes 01'-06' have priority over code 07'.
Second digit is to be coded '8' when reconstructive surgery of the primary site is done as part of the planned first course of therapy.
APPENDIX C
SITE-SPECIFIC SURGERY CODES

BREAST
174.0-174.9 Female; 175.9 Male

Code:

No Cancer-Directed Surgery/Unknown

00 No surgical procedure
01 Incisional, needle, or aspiration biopsy of other than primary site
02 Incisional, needle, or aspiration biopsy of primary site
03 Exploratory ONLY (no biopsy)
04 Bypass surgery, -ostomy ONLY (no biopsy)
05 Exploratory ONLY AND incisional, needle or aspiration biopsy of primary site or other sites
06 Bypass surgery, -ostomy ONLY AND incisional, needle or aspiration biopsy of primary site or other sites
07 Non-cancer directed surgery, NOS
09 Unknown if surgery done

Type of Cancer-Directed Surgery

10 Partial/less than total mastectomy (includes segmental mastectomy, lumpectomy, quadrantectomy, tylectomy, wedge resection, nipple resection, excisional biopsy, or partial mastectomy, NOS) WITHOUT dissection of axillary lymph nodes
20 Partial/less than total mastectomy WITH dissection of axillary lymph nodes
30 Subcutaneous mastectomy WITH/WITHOUT dissection of axillary nodes
40 Total (simple) mastectomy (breast only) WITHOUT dissection of axillary lymph nodes
50 Modified radical/total (simple) mastectomy (may include portion of pectoralis major) WITH dissection of axillary lymph nodes
60 Radical mastectomy WITH dissection of majority of pectoralis major WITH dissection of axillary lymph nodes
70 Extended radical mastectomy (code 60 PLUS internal mammary node dissection; may include chest wall and ribs)
80 Surgery of regional and/or distant site(s)/node(s) ONLY
90 Mastectomy, NOS; Surgery, NOS

Revised January, 1989 THE SEER PROGRAM CODE MANUAL -- 1988 175
Note: Codes '10'-'78' apply to unilateral resection of primary cancer.
Ignore removal of fragments or tags of muscle; removal of pectoralis minor; resection of pectoralis muscles, NOS; and resection of fascia with no mention of muscle.
Oophorectomy, adrenalectomy, and hypophysectomy will be coded as Endocrine (Hormone/Steroid) Therapy.
Codes '10'-'90' have priority over codes '00'-'09'.
Codes '10'-'78' have priority over codes '80'-'90'.
Surgery of primary not included in any category should be coded '90'.
In the range '10'-'78', the higher code has priority.
Codes '01'-'07' have priority over code '09'.
In the range '01'-'05', the higher code has priority.
Codes '01'-'07' and '09' cannot be used in combination with codes '10'-'90'.
Codes '01'-'06' have priority over code '07'.
Second digit is to be coded '8' when reconstructive surgery of the primary site is done as part of the planned first course of therapy.
### APPENDIX C
#### SITE-SPECIFIC SURGERY CODES

### CERVIX UTERI

**Code:**

- **No Cancer-Directed Surgery/Unknown**
  - 00 No surgical procedure
  - 01 Incisional, needle, or aspiration biopsy of other than primary site
  - 02 Incisional, needle, or aspiration biopsy of primary site
  - 03 Exploratory ONLY (no biopsy)
  - 04 Bypass surgery, -ostomy ONLY (no biopsy)
  - 05 Exploratory ONLY AND incisional, needle or aspiration biopsy of primary site or other sites
  - 06 Bypass surgery, -ostomy ONLY AND incisional, needle or aspiration biopsy of primary site or other sites
  - 07 Non-cancer directed surgery, NOS
  - 09 Unknown if surgery done

### Type of Cancer-Directed Surgery

- 10 Cryosurgery; laser surgery WITHOUT pathology specimen
- 15 Dilatation and curettage (in situ ONLY); endocervical curettage (in situ ONLY)
- 20 Local surgical excision; excisional biopsy; trachelectomy; amputation of cervix or cervical stump; laser surgery WITH pathology specimen; conization
- 30 Total/pan/simple hysterectomy (includes both corpus and cervix uteri) WITHOUT removal of tubes and ovariesWithout dissection of lymph nodes
- 35 *Total/pan/simple hysterectomy (includes both corpus and cervix uteri) WITHOUT removal of tubes and ovaries WITH dissection of lymph nodes
- 40 Total/pan/simple hysterectomy WITH removal of tube(s) and ovary(ies) WITHOUT dissection of lymph nodes
- 50 Modified radical/extended hysterectomy (includes uterus, tube(s), ovary(ies), and para-aortic and pelvic lymph nodes, and may include vaginal cuff); radical hysterectomy (includes uterus, tube(s), ovary(ies), vagina, all parametrial and paravaginal tissue, and para-aortic and pelvic lymph nodes); Wertheim's operation
- 60 Hysterectomy, NOS

*Effective date January 1, 1990.*
APPENDIX C
SITE-SPECIFIC SURGERY CODES

CERVIX UTERI (cont'd)

70 Pelvic Exenteration (partial or total)
   Anterior exenteration (includes bladder, distal ureters, and
genital organs with their ligamentous attachments and pelvic
lymph nodes)
   Posterior exenteration (includes rectum and rectosigmoid with
ligamentous attachments and pelvic lymph nodes)
   Total exenteration (includes removal of all pelvic contents and
pelvic lymph nodes)
   Extended exenteration (includes pelvic blood vessels or bony
pelvis)

80 Surgery of regional and/or distant site(s)/node(s) ONLY

90 Surgery, NOS

NOTE: Codes 30, 35 and 40 may include a portion of vaginal cuff.
   Ignore incidental removal of appendix.
   Ignore omentectomy if it was the only surgery performed in
   addition to hysterectomy.
   Ignore surgical approach, i.e., abdominal or vaginal.
   For invasive cancers only, dilatation and curettage is to be
   coded as an incisional biopsy.
   Codes '10'-'90' have priority over codes '00'-'09'.
   Codes '10'-'78' have priority over codes '80'-'90'.
   Surgery of primary not included in any category should be coded
   '90'.
   In the range '10'-'78', the higher code has priority.
   Codes '01'- '07' have priority over code '09'.
   In the range '01'- '06', the higher code has priority.
   Codes '01'- '07' and '09' cannot be used in combination with codes
   '10'- '90'.
   Codes '01'- '06' have priority over code '07'.
   Second digit is to be coded '8' when reconstructive surgery of
   the primary site is done as part of the planned first course
   of therapy.
# APPENDIX C
## SITE-SPECIFIC SURGERY CODES

### CORPUS UTERI

182.0-182.8

**Code:**

- No Cancer-Directed Surgery/Unknown

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>No surgical procedure</td>
</tr>
<tr>
<td>01</td>
<td>Incisional, needle, or aspiration biopsy of primary site</td>
</tr>
<tr>
<td>02</td>
<td>Incisional, needle, or aspiration biopsy of primary site (no biopsy)</td>
</tr>
<tr>
<td>03</td>
<td>Exploratory ONLY</td>
</tr>
<tr>
<td>04</td>
<td>Bypass surgery, -ostomy (no biopsy)</td>
</tr>
<tr>
<td>05</td>
<td>Exploratory ONLY AND incisional, needle or aspiration biopsy of primary site or other sites</td>
</tr>
<tr>
<td>06</td>
<td>Bypass surgery, -ostomy ONLY AND incisional, needle or aspiration biopsy of primary site or other sites</td>
</tr>
<tr>
<td>07</td>
<td>Non-cancer directed surgery, NOS</td>
</tr>
<tr>
<td>09</td>
<td>Unknown if surgery done</td>
</tr>
</tbody>
</table>

**Type of Cancer-Directed Surgery**

- 10 Polypectomy; myomectomy (simple excision); simple excision, NOS
- 20 Subtotal hysterectomy: supracervical hysterectomy; fundectomy (cervix left in place WITH/WITHOUT removal of tubes and ovaries)
- 30 Total/pan/simple hysterectomy (includes both corpus and cervix uteri) WITHOUT removal of tubes and ovaries, WITHOUT dissection of lymph nodes
- 35 Total/pan/simple hysterectomy (includes both corpus and cervix uteri) WITHOUT removal of tubes and ovaries, WITH dissection of lymph nodes
- 40 Total/pan/simple hysterectomy WITH removal of tube(s) and ovary(ies) WITHOUT dissection of lymph nodes
- 50 Modified radical/extended hysterectomy (includes uterus, tube(s), ovary(ies), and para-aortic and pelvic lymph nodes, and may include vaginal cuff); radical hysterectomy (includes uterus, tube(s), ovary(ies), vagina, and all parametrial and paravaginal tissue, and para-aortic and pelvic lymph nodes); Wertheim's operation
- 60 Hysterectomy, NOS

*: Effective date January 1, 1990.
APPENDIX C
SITE-SPECIFIC SURGERY CODES

CORPUS UTERI (cont'd)

70 Pelvic Exenteration (partial or total)
   Anterior exenteration (includes bladder, distal ureters, and
   genital organs with their ligamentous attachments and pelvic
   lymph nodes)
   Posterior exenteration (includes rectum and rectosigmoid with
   ligamentous attachments and pelvic lymph nodes)
   Total exenteration (includes removal of all pelvic contents and
   pelvic lymph nodes)
   Extended exenteration (includes pelvic blood vessels or bony
   pelvis)

80 Surgery of regional and/or distant site(s)/node(s) ONLY

90 Surgery, NOS

NOTE: Codes 30, 35 and 40 may include a portion of vaginal cuff.
Ignore incidental removal of appendix.
Ignore omentectomy if it is the only surgery performed in
   addition to hysterectomy.
Ignore surgical approach, i.e., abdominal or vaginal.
For invasive and in situ cancers, dilatation and curettage is to
   be coded as an incisional biopsy.
Codes '10'-'90' have priority over codes '00'-'09'.
Codes '10'-'78' have priority over codes '80'-'90'.
Surgery of primary not included in any category should be coded
   '90'.
In the range '10'-'78', the higher code has priority.
Codes '01'-'07' have priority over code '09'.
In the range '01'-'06', the higher code has priority.
Codes '01'-'07' and '09' cannot be used in combination with codes
   '10'-'90'.
Codes '01'-'06' have priority over code '07'.
Second digit is to be coded '8' when reconstructive surgery of
   the primary site is done as part of the planned first course of therapy.
APPENDIX C
SITE-SPECIFIC SURGERY CODES

ALL OTHER SITES

150.0-150.9, 152.0-152.9, 154.2-156.9, 158.0-160.9, 162.0, 163.0-165.9, 169.0-169.1, 169.3-169.9, 179.9, 181.9, 183.2-184.9, 187.1-187.9, 189.3-192.9, 194.0-195.8, 199.9

Code:

No Cancer-Directed Surgery/Unknown

00 No surgical procedure
01 Incisional, needle, or aspiration biopsy of other than primary site
02 Incisional, needle, or aspiration biopsy of primary site
03 Exploratory ONLY (no biopsy)
04 Bypass surgery, -ostomy ONLY (no biopsy)
05 Exploratory ONLY AND incisional, needle or aspiration biopsy of primary site or other sites
06 Bypass surgery, -ostomy ONLY AND incisional, needle or aspiration biopsy of primary site or other sites
07 Non-cancer directed surgery, NOS
09 Unknown if surgery done

Type of Cancer-Directed Surgery

10 Cryosurgery
20 Cautery, fulguration, laser surgery WITHOUT pathology specimen
30 Laser surgery WITH pathology specimen
35 Excisional biopsy; polypectomy; excision of lesion
40 Partial/simple removal of primary site WITHOUT dissection of lymph nodes
50 Partial/simple removal of primary site WITH dissection of lymph nodes
55 Stated as "debulking" WITH or WITHOUT dissection of lymph nodes
60 Radical surgery (primary site plus partial or total removal of other organs)
80 Surgery of regional and/or distant site(s)/node(s) ONLY
90 Surgery, NOS
ALL OTHER SITES

NOTE: Codes '10'-'90' have priority over codes '00'-'09'.
Codes '10'-'78' have priority over codes '80'-'90'.
Surgery of primary not included in any category should be coded '90'.
In the range '10'-'78', the higher code has priority.
Codes '01'-'07' have priority over code '09'.
In the range '01'-'06', the higher code has priority.
Codes '01'-'07' and '09' cannot be used in combination with codes '10'-'90'.
Codes '01'-'06' have priority over code '07'.
Second digit is to be coded '8' when reconstructive surgery of the primary site is done as part of the planned first course of therapy.
## APPENDIX D
CODING EXCEPTIONS FOR PRE-1988 CASES

### SITE SPECIFIC SURGERY (cont'd)

**SITE: Breast (174.0-174.9, 175.9)**

<table>
<thead>
<tr>
<th>OLD DEFINITION</th>
<th>NEW DEFINITION</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Partial/less than total mastectomy (incl. segmental mastectomy, lumpectomy, quadrantectomy, tylectomy, wedge resection, nipple resection, excisional biopsy, or partial mastectomy, NOS) WITHOUT dissection of axillary lymph nodes</td>
<td>10 Partial/less than total mastectomy (includes segmental mastectomy, lumpectomy, quadrantectomy, tylectomy, wedge resection, nipple resection, excisional biopsy, or partial mastectomy, NOS) WITHOUT dissection of axillary lymph nodes</td>
</tr>
<tr>
<td>Code 1 WITH dissection of axillary lymph nodes</td>
<td>20 Partial/less than total mastectomy WITH dissection of axillary lymph nodes</td>
</tr>
<tr>
<td>3 Subcutaneous mastectomy WITH/WITHOUT dissection of axillary lymph nodes</td>
<td>30 Subcutaneous mastectomy WITH/WITHOUT dissection of axillary nodes</td>
</tr>
<tr>
<td>4 Total (simple) mastectomy (breast only) WITHOUT dissection of axillary lymph nodes</td>
<td>40 Total (simple) mastectomy (breast only) WITHOUT dissection of axillary lymph nodes</td>
</tr>
<tr>
<td>5 Total (simple)/modified radical mastectomy (may include portion of pectoralis major) WITHOUT dissection of axillary lymph nodes</td>
<td>50 Modified radical/total (simple) mastectomy (may include portion of pectoralis major) WITHOUT dissection of axillary lymph nodes</td>
</tr>
<tr>
<td>6 Radical mastectomy WITH dissection of all of pectoralis major WITH dissection of axillary lymph nodes</td>
<td>60 Radical mastectomy WITH dissection of majority of pectoralis major WITH dissection of axillary lymph nodes</td>
</tr>
<tr>
<td>7 Extended radical mastectomy (code 6 + internal mammary node dissection; may include chest wall and ribs)</td>
<td>70 Extended radical mastectomy (code 60 PLUS internal mammary node dissection; may include chest wall and ribs)</td>
</tr>
</tbody>
</table>
APPENDIX D
CODING EXCEPTIONS FOR PRE-1988 CASES

SITE SPECIFIC SURGERY (cont'd)

SITE: Breast (174.0-174.9, 175.9) (cont'd)

<table>
<thead>
<tr>
<th>OLD DEFINITION</th>
<th>NEW DEFINITION</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 Surgery of regional and/or distant site(s)/nodes ONLY</td>
<td>80 Surgery of regional and/or distant site(s)/node(s) ONLY</td>
</tr>
<tr>
<td>9 Mastectomy, NOS; Surgery, NOS</td>
<td>Mastectomy, NOS; Surgery, NOS</td>
</tr>
</tbody>
</table>
INDEX

Administrative codes, 2, 50, 51, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131
Age/site/histology interfield review, 125
Computer record format, 2
General description, 122
Histology/behavior interfield review, 124
Lymphoma or leukemia/diagnostic confirmation interfield review, 129
Reporting source/sequence number interfield review, 129
SEER Code summary, 50, 51
Sequence number/diagnostic confirmation interfield review, 126
Sequence number/ill-defined site interfield review, 130
Site/histology/laterality/sequence number interrecord review, 127
Site/type interfield review, 123
Surgery/diagnostic confirmation interfield review, 128
Adrenocorticotropic hormones (See Therapy, endocrine), 111
Age at diagnosis, 1, 41, 67
 Codes, 67
 Coding rules, 67
 Computer record format, 1
 SEER Code summary, 41
Age/site/histology interfield review, 2, 50, 125
 Codes, 125
 Coding rules, 125
 Computer record format, 2
 SEER Code summary, 50
Altemeier operation, 163
Ambiguous terms, 7
Autopsy Only, 200
Date of diagnosis, 57, 74, 75
Date therapy initiated, 57, 100, 101
Diagnostic procedures, 200
Follow-up, type of, 120
Radiation to the brain and central nervous system, 108
Therapy, 100, 200
 Coding rules
 1988+, 57
Tumor markers, 57

B-cell (See Morphology, B-cell), 87, 88
Basic record identification, 1, 39, 52, 53, 54, 55
 Computer record format, 1
 General description, 52
 SEER Code summary, 39, 47, 48, 49, 50, 51
Behavior (See Morphology, behavior), 1, 45
Billroth surgical procedures, 159
Biological response modifiers (See Therapy), 2, 48, 112, 256
Birthday (See Date of birth), 66
Birthplace (See Place of birth), 63, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155
Brain and central nervous system
  Radiation to, 109
Breast
 Endocrine therapy, 111
  Radiation, 111
  Surgery, 111
Therapy, 111

Case number, 1, 39, 54
Codes, 54
Coding rules, 54
Computer record format, 1
SEER Code summary, 39

Cause of death (See Underlying cause of death), 119
Census tract, 1, 41, 62, 63
Codes, 62
Coding rules, 62
1973-78, 62, 200
1979-87, 62, 200
1988+, 62
Coding system of, 63
Computer record format, 1
SEER Code summary, 41

Cervix uteri
Follow-up, 120
Chemotherapy, 2, 47, 110, 254
Codes, 110, 254
Coding rules, 110, 254
Computer record format, 2
Hormones and, 110
SEER Code summary, 47

Chronological sequence (See Sequence number), 76, 77
Coding system for census tract, 1, 41, 63
Codes, 63
Coding rules
1973-78, 200
1979-87, 200
1988+, 63
Computer record format, 1
SEER Code summary, 41

Coding system for extent of disease, 2, 45, 95, 218, 219, 220, 221
Codes, 95
Coding rules
1973-82, 217, 218, 219, 220, 221
1983-87, 218
1988+, 95
Computer record format, 2
Death Certificate Only
1973-82, 200, 218, 219, 220, 221
1983-87, 200
1988+, 57
SEER Code summary, 43
1983-87, 217

Compatible with, ambiguous term, 7
Consistent with, ambiguous term, 7

County, 1, 41, 61, 122, 134, 135, 136, 137, 138
Codes, 61, 132, 134, 135, 136, 137, 138
Computer record format, 1
SEER Code summary, 41

Date
Birth (See Date of birth), 66
Death (See Date of last follow-up or of death), 115
Diagnosis (See Date of diagnosis), 74
Follow-up (See Date of last follow-up or of death), 116
Last follow-up (See Date of last follow-up or of death), 116
Therapy initiated (See Date therapy initiated), 102

Date of birth, 1, 41, 66
Codes, 66
Coding rules, 66
Computer record format, 1
SEER Code summary, 41

Date of diagnosis, 1, 44, 74, 75
Approximation of, 74, 75
Autopsy Only, 57, 74, 75
Codes, 74, 75
Coding rules, 74, 75
Computer record format, 1
Date therapy initiated and, 75
Death Certificate Only, 57, 74, 75
SEER Code summary, 44

Date of last follow-up or of death, 2, 49, 116
Codes, 116
Coding rules, 116
Computer record format, 2
SEER Code summary, 49

Date therapy initiated, 2, 46, 101, 102
Autopsy Only, 57
Codes, 101, 102
Coding rules, 101, 102
Computer record format, 2
Death Certificate Only, 57
SEER Code summary, 46

Death Certificate Only, 200
C D ing system for extent of disease
1973-82, 200, 218
1983-87, 200
1988+, 57
Date of diagnosis, 57, 74, 75
Date therapy initiated, 57, 100, 101
Diagnostic confirmation, 57, 90, 91
Extent of disease, 97, 218
1973-82, 200, 218
1983-87, 200, 218
1988+, 57, 97
Follow-up, type of, 120
Radiation sequence with surgery, 57, 100
Radiation to the brain and central nervous system, 57, 108
Surgery, site-specific, 100
Therapy, 100, 200
Coding rules
1988+, 57
Tumor markers, 57

Demographic information, 1, 41, 42, 43, 57, 59, 60, 61, 62, 63, 65, 66, 67, 68, 69, 70, 71, 132, 134, 135, 136, 137, 138, 202, 203
Computer record format, 1
General description, 59
SEER Code summary, 41, 42, 43

Description of this neoplasm, 1, 2, 44, 45, 73, 74, 75, 76, 77, 78, 79, 81, 82, 83, 84, 85, 86, 87, 88, 90, 96, 97, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221
Coding system for extent of disease, 95, 217, 218, 219, 220, 221

Computer record format, 1, 2
Diagnostic confirmation, 90, 91, 204
Diagnostic procedures, 93, 205, 206, 207, 208, 209, 211, 212, 213, 214, 215, 216
Extent of disease, 96, 97, 217, 218, 219, 220, 221
SEER Code summary, 44, 45
Diagnostic date (See Date of diagnosis), 74, 75
Diagnostic confirmation, 1, 45, 90, 91
Codes, 90, 91, 204
Coding rules, 90, 91, 204
Computer record format, 1
Death Certificate Only, 57, 90, 91
SEER Code summary, 45
Diagnostic procedures, 1, 45, 93, 205, 206, 207, 208, 209, 211, 212, 213, 214, 215, 216
Autopsy Only, 200, 206
Changes over time, 206
Coding rules, 207, 208, 209, 211, 212, 213, 214, 215, 216

Breast, 211
Brain, 209
Cervix uteri, 212
Colon, 208
Cervix uteri, 213
Hodgkin's disease, 216
Lung, 209
Melanoma of skin, 210
Non-Hodgkin's lymphoma, 216
Prostate, 214
Rectum, 208
Stomach, 207
Coding rules, 205, 206, 207, 208, 209, 211, 212, 213, 214, 215, 216
1973-82, 205, 206, 207, 208, 209, 211, 212, 213, 214, 215, 216
1983-87, 205, 206, 207, 208, 209, 211, 212, 213, 214, 215, 216
1988+, 93, 206
Computer record format, 1
Death Certificate Only, 206
Coding rules, 200
Extent of disease and, 205
SEER Code summary, 45
Time period for determining, 205
Different histologies, 8, 83, 84
Coding rules, 83, 84
Multiple primaries and, 8, 9, 10
Differentiation (See Morphology, differentiation), 87, 88
Double-blind clinical trial, 113, 257
Dumamel operation, 163

Endocrine (hormone/steroid) therapy (See Therapy, endocrine), 2
Endocrine radiation (See Therapy, endocrine), 111, 235
Endocrine surgery (See Therapy, endocrine), 111, 255
Endocrine therapy (See Therapy, endocrine), 111, 235
EOD (See Extent of disease), 217
Equivocal, ambiguous term, 7
Expanded (13 digit) site-specific (See Extent of disease), 2
Extent of disease, 2, 96, 97, 217, 218, 219, 220, 221
Autopsy reports and, 97, 218
Coding rules, 97

Computer record format, 2

Death Certificate Only

1973-82, 220, 221
1973-87, 217, 218, 219
1988+, 97

Determination of sequence number and, 76, 77
Diagnostic procedures and, 205
Evaluating reliability, 205
Non-specific EOD code, 218, 219, 220, 221
Radiation and, 97, 217
SEER 10-digit Extent of disease 1988+, 97
SEER 4-digit Extent of disease 1983-87, 218, 219

Selecting appropriate EOD scheme
1973-82, 218, 219, 220

Registry exceptions
New Jersey, 218, 219, 220, 221
San Francisco-Oakland, 218, 219, 220, 221

1973-87, 218

Registry exceptions
New Jersey, 218
San Francisco-Oakland, 218

Thirteen-digit EOD, 218, 219, 220, 221

Time period for determining
1973-1987, 217
1988+, 97

Two-digit site-specific EOD code, 218, 219, 220, 221

First course of cancer-directed therapy (See Therapy), 2, 46, 99, 100, 101, 102, 103, 106, 107, 108, 109, 110, 111, 112, 113, 255, 256, 257

Follow-up information, 2, 49, 115, 116, 117, 118, 119, 120

Date of last follow-up or of death, 116
ICD code revision used for cause of death, 118

Introduction, 115
SEER Code summary, 49
Type of follow-up, 120
Underlying cause of death, 119
Vital status, 117

Follow-up, type of, 2, 120

Codes, 120
Coding rules, 120

Computer record format, 2

Geocodes, 61, 62, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155
Census tract, 62
County, 61, 133, 134, 135, 136, 137, 138
Place of birth, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155
Grade, differentiation, or cell indicator (See Morphology, grade, differentiation, or cell indicator), 43
Grading (See Morphology, grade), 87, 88

Hartmann operation, 163
Histologic type (See Morphology, histology), 45
Histology/behavior interfield review, 2, 50, 124
  Codes, 124
  Coding rules, 124
  Computer record format, 2
  SEER Code summary, 50
Hormone therapy (See Therapy, endocrine), 111, 255

ICD Code revision used for cause of death, 2, 49, 118
  Codes, 118
  Coding rules, 118
  Computer record format, 2
  SEER Code summary, 49
Immunotherapy (See Therapy, biological response modifiers), 112, 256
In situ, 86
  Microinvasive and, 86
  Synonymous terms, 86
Information source, 1, 40, 56, 57
  Computer record format, 1
  SEER Code summary, 40
Interfield review
  Age/site/histology, 125
  Histology/behavior, 124
  Lymphoma or leukemia/diagnostic confirmation, 131
  Reporting source/sequence number, 129
  Sequence number/diagnostic confirmation, 126
  Sequence number/ill-defined site, 130
  Site/type, 123
  Surgery/diagnostic confirmation, 128
Interrecord review
  Site/histology/laterality/sequence number, 127
Kaposi's sarcoma
  Multiple primaries, 11
  Primary site, 78
Laterality at diagnosis, 1, 44, 81, 82
  Codes, 81, 82
  Coding rules, 81, 82
  Computer record format, 1
  SEER Code summary, 44
  Sites requiring, 81, 82
Leukemia
  Endocrine therapy, 111
  Primary site, 78
  T-cell, B-cell, or null cell, 87, 88
  Therapy, 107, 108, 111
    Definition first course, 99
    Radiation, 107, 108, 109
    Radiation to the brain and central nervous system, 107, 108, 109
    Time period for determining, 99
Leukemia or lymphoma diagnostic confirmation interfield review, 3, 31, 131
  Codes, 131
  Coding rules, 131
  Computer record format, 3
  SEER Code summary, 51
Lung
  Therapy, 107, 108

Radiation, 107, 108, 109
Radiation to the brain and central nervous system, 107, 108, 109
Lymph node dissection-definition, 104, 105

Lymphoma

Endocrine therapy, 111
Primary site, 78
Extranodal, 78
Lymph nodes, 78
Nodal, 78
Surgery, 104, 105
T-cell, B-cell, or null cell, 87, 88

Marital status at diagnosis, 1, 43, 71
Codes, 71
Computer record format, 1
SEER Code summary, 43

Microinvasive

In situ and, 86
Microscopic confirmation, 85, 90, 91
Miles operation, 163

Morphology, 1, 43, 83, 84, 85, 86, 87, 88
B-cell, 87, 88
Coding rules, 87, 88
Behavior, 83, 84, 86
Coding rules, 83, 84, 86
Computer record format, 1
SEER Code summary, 43
Coding rules, 83, 84
Computer record format, 1
Determination of sequence number and, 76, 77
Differentiation, 83, 84, 87, 88
Coding rules, 87, 88
Grade, 83, 84, 87, 88
Coding rules, 87, 88
Grade, differentiation, or cell indicator, 1
Computer record format, 1
SEER Code summary, 43

Histologic type

Computer record format, 1
SEER Code summary, 43
Histology, 83, 84, 85
Coding rules, 83, 84, 85
Microscopic confirmation and, 85
Mixed histologies and, 8, 83, 84
Null cell, 87, 88
Coding rules, 87, 88
SEER Code summary, 43
Site-specific terms, 76
T-cell, 87, 88
Coding rules, 87, 88
T-cell, B-cell, null cell, 82, 84

Multiple myeloma

Endocrine therapy, 111

Multiple primaries, 7, 8, 9, 10, 11
Behavior and, 7
Bilateral sites and, 10
Bladder, 9
Colon, 9
Date of diagnosis and, 7, 8, 9, 10, 11
Different histologies and, 8
Histology and, 7, 8, 11
Kaposi’s sarcoma, 11
Mixed histologies and, 8
Ovary, bilateral, 10
Paired organs and, 7, 10
Rectum, 9
Retinoblastomas, bilateral, 10
Rules for determining, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36
Same histology and, 8, 9
Sequence number and, 76, 77
Simultaneous, 8, 9
Multiple lesions, 9, 10
Single lesion and, 7, 8, 9, 10, 11
Site (3-digit) and, 7, 8
Subsites, 75
Subsites (4-digit) and, 8
Bone, 8
Colon, 8
Connective tissue, 8
Rectum, 8
Skin, melanoma of, 8
Synchronous, 8
Wilms’s tumor, bilateral, 10

Neoplasm
Description of this, 73, 74, 75, 76, 77, 78, 79, 81, 82, 83, 84, 85, 86, 87, 88, 90, 96, 97, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 220, 221
Coding system for extent of disease, 95, 217, 218, 219, 220, 221
Diagnostic confirmation, 90, 91, 204
Diagnostic procedures, 93, 205, 206, 207, 208, 209, 211, 212, 213, 214, 215, 216
Extent of disease, 96, 97, 217, 218, 219, 220, 221
Non-reportable cases (See Reportable cases (SEER)), 86
Nonspecific two-digit (See Extent of disease), 2
Null cell (See Morphology, null cell), 87, 88

Other cancer-directed therapy, 48
SEER Code summary, 48

Other cancer-directed therapy (See Therapy), 2
Other therapy (See Therapy), 113, 257
Ovary, bilateral, 10

Palliative therapy, 100
Patient identification, 52
Place of birth, 1, 41, 65
Codes, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155
Coding rules, 65
Computer record format, 1
SEER Code summary, 41
Place of residence at diagnosis (See Residence), 60
Possible, ambiguous term, 7
Primary site, 1, 44, 78, 79
Coding rules, 78, 79
Computer record format, 1
Kaposi's sarcoma, 78
Leukemia, 78
Lymphoma, 78
Metastatic site and, 78, 79
Multiple primaries and, 79
Secondary site and, 78, 79
SEER Code summary, 44
Probable, ambiguous term, 7
Prostate
Endocrine therapy, 111
Radiation, 111
Surgery, 111
Therapy, 111
Pull-through operation, 163

Questionable, ambiguous term, 7
Race, 1, 42, 68
Codes, 68, 202, 203
Coding rules, 68, 202, 203
Computer record format, 1
SEER Code summary, 42
Radiation, 2, 46, 107, 108, 109, 252
Codes, 107, 252
Coding rules, 107, 252
Computer record format, 2
Extent of disease and, 97, 218
Leukemia, 107, 108
Lung, 107, 108
SEER Code summary, 46
To the brain and central nervous system, 107, 108, 109
Codes, 108
Coding rules, 108
Radiation sequence with surgery, 2, 47, 109, 253
Codes, 109, 253
Coding rules, 109, 253
Computer record format, 2
SEER Code summary, 47
Radiation to the brain and central nervous system, 2, 47, 252
Autopsy Only, 108
Codes, 252
Coding rules, 252
Computer record format, 2
Death Certificate Only, 108
SEER Code summary, 47
Ranikin operation, 163
Reason for no cancer-directed surgery, 2, 46, 106, 200, 251
Autopsy Only, 106, 200
Codes, 106, 251
Coding rules, 106, 251
Computer record format, 2
Death Certificate Only, 100

SEER Code summary, 46
Record identification, 32
Record number, 1, 39, 53
Codes, 53
Coding rules, 55
Computer record format, 1
SEER Code summary, 39
Registry (See SEER Participant), 53
Reportable cases (SEER), 7, 53, 86
Ambiguous terms, 6
Date of diagnosis, 7
SEER Participant, 7, 53
Elevation of usual ICD-O behavior code, 7, 86
Residency at diagnosis, 7, 53
Skin, 7
Genital sites, 7
Reporting source/sequence number interfield review, 51, 129
Codes, 129
Coding rules, 129
SEER Code summary, 51
Reporting source, type of, 1, 40, 57
Codes, 57, 201
Coding rules, 57, 201
Computer record format, 1
SEER Code summary, 40
Residence at diagnosis, 1, 41, 60
Census tract, 62
Coding system for census tract, 63
Computer record format, 1
County, 61, 133, 134, 135, 136, 137, 138
SEER Code summary, 41
Retinoblastomas, bilateral, 10

SEER Code summary, 38, 39, 40, 41, 42, 43, 44, 45, -6, 47, 48, 49, 50, 51
General description, 38
SEER Participant, 1, 39, 53
Codes, 33
Computer record format, 1
SEER Code summary, 39
Year reporting started, 53
SEER 1-digit (See Extent of disease), 2
SEER 2-digit (See Extent of disease), 2
Sequence number, 1, 44, 76, 77
Codes, 76, 77
Coding rules, 76, 77
Computer record format, 1
Extent of disease and, 76, 77
Morphology and, 76, 77
Multiple primaries and, 76, 77
SEER Code summary, 40
Sequence number diagnostic confirmation interfield review, 2, 50, 126
Codes, 126
Coding rules, 126
Computer record format, 2
SEER Code summary, 50
Sequence number ill-defined site interfield review, 3, 51, 130
Codes, 130

Caching rules, 130
Computer record format, 3
SEER Code summary, 51
Sex, 1, 42, 70
Codes, 70
Computer record format, 1
SEER Code summary, 42
Site-specific surgery, 2, 46
Computer record format, 2
SEER Code summary, 46
Site/histology/laterality/sequence number interrecord review, 2, 50, 127
Codes, 127
Coding rules, 127
Computer record format, 2
SEER Code summary, 50
Site/type interfield review, 2, 50, 123
Codes, 123
Coding rules, 123
Computer record format, 2
SEER Code summary, 50
Skin, 7
Genital sites, 7
Non-reportables, 7
Soave submucosal resection, 163
Spanish origin (See Spanish surname or origin), 69, 202, 203
Spanish surname or origin, 1, 42, 69
Codes, 69, 202, 203
Coding rules, 69, 202, 203
Computer record format, 1
SEER Code summary, 42
Steroids (See Therapy, endocrine), 111, 255
Suggests, ambiguous term, 7
Codes
Priority of, 104, 105
Computer record format, 2
Endocrine (See Therapy, endocrine), 111, 255
Extent of disease and, 97, 218
Lymph node dissection-definition, 104, 105
Lymphoma, 104, 105
Multiple primaries and, 104, 105
No cancer-directed, 106
No cancer-directed (1973-87), 248
Radiation sequence with, 109
Reason for no cancer-directed, 106, 251
Autopsy Only, 100
Death Certificate only, 100
Reconstructive, 104, 105, 248
SEER Code summary, 42
All sites (1973-82), 222, 248
Bladder, 103, 189, 190, 244, 245
Bone, 171, 172
Breast, 103, 175, 176, 233, 234
Bronchus, 103, 169, 170, 229, 230
Cervix uteri, 103, 177, 179, 235, 236, 237, 249, 250
Codes, 103
Coding rules, 103
Colon, 103, 161, 162, 226
Connective and other soft tissue, 171, 172
Corpus uteri, 103, 180, 182, 238, 239
Kidney, 103, 191, 192, 246, 247
Larynx, 103, 167, 168
Lung, 103, 169, 170, 229, 230
Lymph nodes, 195, 196
No cancer-directed (1983-87), 223
Oral cavity, 103, 157, 158
Ovary, 103, 183, 184, 240, 241, 249
Pancreas, 103, 165, 166
Prostate, 103, 185, 186, 242, 243
Rectosigmoid, 163, 164, 227, 228
Rectosigmoid, rectum, 103
Rectum, 103, 163, 164, 227, 228
Renal pelvis, 103, 191, 192, 246, 247
Sites, all other (1983-87), 222, 250
Sites, all other (1988+), 197, 199
Skin, 103, 173, 174
Skin, melanoma of, 231, 232, 249, 250
Spleen, 195, 196
Stomach, 103, 159, 160, 224, 225
Testis, 103, 187, 188
Thyroid, 103, 193, 194
Ureter, 103, 191, 192, 246, 247
Surgery/diagnostic confirmation interfield review, 2, 50, 128
Codes, 128
Coding rules, 128
Computer record format, 2
SEER Code summary, 50
Suspect, ambiguous term, 7
Suspicious, ambiguous term, 7
Swenson operation, 163

T-cell (See Morphology, T-cell), 87, 88
Autopsy Only, 57, 100, 101, 108
Biological response modifiers, 2, 112, 256
Codes, 112, 256
Coding rules, 112, 256
Computer record format, 2
SEER Code summary, 48
Chemotherapy, 2, 47, 110, 254
Codes, 110
Coding rules, 110
Computer record format, 2
Hormones and, 110
SEER Code summary, 47
Computer record format, 2
Date initiated, 46, 101, 102
Autopsy Only, 57, 101

Biopsy, 101, 102
Codes, 101, 102
Coding rules, 101, 102
Death Certificate Only, 57, 101
No cancer-directed, 101, 102
SEER Code summary, 46

Death Certificate Only, 57, 100, 101, 108

Definition
Cancer-directed, 99, 100
First course, 99, 100
Planned, 99, 100
Time period for determining, 99, 100
Leukemia, 99, 100
Sites other than leukemia, 99, 100
No cancer-directed, 100

Endocrine, 2, 48, 111, 253
Chemotherapy and, 111
Codes, 111, 253
Coding rules, 111, 253
Computer record format, 2
SEER Code summary, 48

Experimental, 113, 257

Hormone, 2, 48, 111, 253

Computer record format, 2

Leukemia
Radiation to the brain and central nervous system, 108
Autopsy Only, 57, 100

Lung
Radiation to the brain and central nervous system, 108
Autopsy Only, 57, 100

No cancer-directed
Coding rules, 100
Date initiated, 100, 101
Other cancer-directed, 2, 48, 113, 257
Codes, 113, 257
Coding rules, 113, 257
Computer record format, 2
SEER Code summary, 48

Palliative, 100
Radiation, 2, 46, 107, 108, 109, 252
Codes, 107
Coding rules, 107
Computer record format, 2
Leukemia, 107
Lung, 107
SEER Code summary, 46

Radiation sequence with surgery, 2, 47, 109, 253
Codes, 109
Coding rules, 109
Computer record format, 2
SEER Code summary, 47

Radiation to the brain and central nervous system, 2, 47, 107, 108, 109, 252
Autopsy Only, 100, 108
Codes, 108
Coding rules, 108
Computer record format, 2
Death Certificate Only, 100, 108
Leukemia, 108
  Autopsy Only, 57, 100
Lung, 108
  Autopsy Only, 57, 100
SEER Code summary, 47
Reason for no cancer-directed surgery, 106
Codes, 106
  Coding rules, 106
SEER Code summary, 46, 47, 48
Steroid, 2, 48, 111, 233
  Computer record format, 2
Surgery, 46, 103, 109, 222, 223, 224, 225, 226, 227, 228, 229, 230,
  231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244,
  245, 246, 247, 248, 249, 250, 251
  Lymph node dissection-definition, 104, 105
Reason for no cancer-directed, 2, 46, 106
  Codes, 106
  Coding rules, 106
  Computer record format, 2
SEER Code summary, 46
Reconstructive, 104, 105
SEER Code summary, 46
Sequence with radiation, 253
Site-specific, 2, 46
  Codes, 103
  Coding rules, 103
  Computer record format, 2
SEER Code summary, 46
Unproven, 113, 237
Time period for determining
  Diagnostic procedures, 205
  Extent of disease, 217
Tumor markers, 1, 89, 89.1, 89.2, 238
  Autopsy Only, 57
  Computer record format, 1
Death Certificate Only, 57
Tumor marker 1, 89.1
  Computer record format, 1
Tumor marker 2, 89.2
  Computer record format, 1
Turnbull operation, 163
Type of follow-up, 49
  SEER Code summary, 49
Type of follow-up (See Follow-up, type of), 120
Type of reporting source (See Reporting source), 1, 57
Type of reporting source sequence number interfield review, 3
  Computer record format, 5
Underlying cause of death, 2, 49, 119
  Codes, 119
  Coding rules, 119
  1973-76, 200
  Computer record format, 2
SEER Code summary, 49
Vital status, 2, 49, 117
  Codes, 117
  Coding rules, 117

Computer record format, 2
SEER Code summary, 49

Wertheim operation, 177, 180
Wilms's tumor, bilateral, 10